Pharmaceuticals & Therapeutics

At BIO 2026, Israeli biotech Can-Fite seeks crucial partnerships for its late-stage cancer and inflammation drugs, built on a unique, safety-focused platform.

Choosing the wrong regulatory partner can derail a market launch. A new guide from Q&C Services offers a veteran's roadmap for de-risking expansion.

SHINE and newcleo are partnering to recycle spent nuclear fuel into new energy, tackling America's 90,000-ton waste problem and reshaping nuclear's future.

China's Huasun Energy is set to debut its Himalaya PLUS 760W module in Europe, leveraging advanced HJT technology to boost efficiency and challenge market norms.

Researchers at Children's Hospital of Philadelphia have pioneered a personalized cartilage graft that could revolutionize surgery for a life-threatening infant airway condition.

FiberSense AG’s new 28-day CGM sensor just won European approval, challenging market leaders. But the real growth signal is its plan to move beyond glucose.

A Swedish pharma company's trial is progressing faster than expected, but the real story is the potential paradigm shift for millions suffering from a neglected disease.

Fox ESS is combining #1 market share with a new factory and a savvy sports marketing campaign. It's a bold strategy to dominate the global energy storage market.

Texas Precious Metals appoints an industrial veteran as President to scale its core e-commerce, freeing its CEO to target global capital markets.

As Lifeway Foods marks 40 years, its celebrity-fueled pop-ups reveal a savvy strategy to dominate the booming wellness market. But is it just marketing?

A new partnership aims to replace plastic nursery cups with a compostable alternative, tackling a massive source of agricultural pollution head-on.

Assertio Holdings delists from Nasdaq after its merger with Zydus. A deep dive into the strategic calculus and the crucial decision facing its debt holders.

As its CFO prepares for a high-stakes J.P. Morgan conference, America's only integrated rare earth producer stands at the nexus of technology, finance, and geopolitics.

Verastem Oncology's new drug enters a pivotal trial for pancreatic cancer, targeting a notorious mutation with a novel dual-action mechanism.

Two agricultural giants are joining forces to deploy rimisoxafen, a novel dual-action herbicide, in a decade-long deal aimed at conquering superweeds.

A $1.2M seed round for orthopaedic AI firm Maia isn't just startup news. It signals a systemic shift from generalist AI to specialized digital engines.

A new Navy contract for Castelion's 'low-cost' Blackbeard missile isn't just about hardware; it's about a strategic shift to mass-produce deterrence.

New appointments bring deep legal and pharma expertise to Canada's Patented Medicine Prices Review Board, signaling a pivotal moment under new 2026 guidelines.

A Stevie Award for Nano-Yield isn't just a trophy; it's a marker for how nanotechnology is creating resilience and value for farmers amid rising costs.

A new bill named for a man failed by the system aims to modernize medical psilocybin access. But can it overcome bureaucratic inertia and position Canada as a leader?